Clinical trial

Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00003812

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention filgrastim Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record etoposide Normalized identity: etoposideView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record topotecan hydrochloride Normalized identity: topotecan hydrochlorideView linked drug · Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention radiation therapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date1999-03-01

PhasePHASE2

Conditions

Lung Cancerverified · MONDO: lung cancer

Interventions

filgrastimBIOLOGICAL

carboplatinDRUG · verified · RxNorm: carboplatin

etoposideDRUG · verified · RxNorm: etoposide

paclitaxelDRUG · verified · RxNorm: paclitaxel

topotecan hydrochlorideDRUG · verified · RxNorm: topotecan hydrochloride

radiation therapyRADIATION

Sponsors & collaborators

Alliance for Clinical Trials in Oncologylead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

New YorkNew York, United States3 ChicagoIllinois, United States3 SyracuseNew York, United States3 St LouisMissouri, United States2 San FranciscoCalifornia, United States2 DurhamNorth Carolina, United States2 Washington D.C.District of Columbia, United States2 RichmondVirginia, United States2 Winston-SalemNorth Carolina, United States2 MemphisTennessee, United States2 BuffaloNew York, United States2 ColumbiaMissouri, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00003812 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.